New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 10, 2014
13:20 EDTGWPHGW jumps ahead of CNN documentary on medical marijuana
Shares of GW Pharmaceuticals (GWPH) are climbing after research firm Piper Jaffray predicted that the stock could be boosted by a CNN documentary on medicinal marijuana expected to air tomorrow night. GW Pharmaceuticals is developing a number of drugs based on cannabinoids, one of the components of marijuana. WHAT'S NEW: After viewing a preview of the CNN documentary, Piper analyst Dr. Joshua Schimmer wrote that the show is likely to include statements from GW Pharmaceuticals and visits to the company. As a result, GW should become more closely associated with medical marijuana, and the stock could rise, Schimmer forecast. Moreover, the documentary will reinforce the effectiveness of using cannabinoids to treat epilepsy, according to the analyst, who noted that GW has created a cannabinoid based drug for the treatment of seizures. The documentary will emphasize the role of drugs derived from cannabinoids in treating other indications, including pain and multiple sclerosis spasticity, according to the analyst. GW is exploring using cannabinoids to treat both of those indications, and the documentary could remind investors that the company can expand beyond its epilepsy treatment, Schimmer contended. Moreover, the documentary could result in the FDA speeding up the approval process for GW's epilepsy drug, according to Schimmer, who reiterated a $97 price target and Overweight rating on GW. PRICE ACTION: In mid-afternoon trading, GW jumped $3.64, or 5%, to $76.05.
News For GWPH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
06:50 EDTGWPHGW Pharmaceuticals commences Epidiolex Phase 2/3 clinical trial
Subscribe for More Information
October 22, 2014
09:21 EDTGWPHOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Dow Chemical (DOW), up 3.7%... iRobot (IRBT), up 12%... Six Flags (SIX), up 13%... GlaxoSmithKline (GSK), up 2%... Broadcom (BRCM), up 7%... Boston Scientific (BSX), up 4.3%... Abbott (ABT), up 1.8%... Yahoo! (YHOO), up 6%. ALSO HIGHER: Blue Earth (BBLU), up 26.4% after CEO says statements in Seeking Alpha blog are "false and misleading."... GW Pharmaceuticals (GWPH), up 5.4% after Epidiolex receives orphan designation from EMA. DOWN AFTER EARNINGS: 3D Systems (DDD), down 15%... Biogen (BIIB), down 7%... Lumber Liquidators (LL), down 13.4%... Norfolk Southern (NSC), down 3%... Angie's List (ANGI), down 8.8%. ALSO LOWER: Nanosphere (NSPH), down 33% after filing secondary, reporting preliminary Q3 revenue... Himax Technologies (HIMX), down 16% after announcing that Google (GOOG) will not exercise an additional investment option in the company... Cree (CREE), down 10.5%, downgraded at DA Davidson and Canaccord following the company's Q1 earnings results... Ocwen Financial (OCN), down 7% after downgraded to Hold at Evercore, downgraded to Neutral at BofA Merrill Lynch... VMware (VMW), down 7.8%, downgraded at Nomura and Raymond James following the company's Q3 results.
05:26 EDTGWPHGW Pharmaceuticals Epidiolex receives orphan designation from EMA
GW Pharmaceuticals announced that the European Medicines Agency, or EMA, has granted orphan designation to GW's investigational product Epidiolex in the treatment of Dravet syndrome, a rare and catastrophic treatment-resistant form of childhood epilepsy. In addition to this orphan designation by the EMA, GW has been granted Fast Track designation by the FDA for Epidiolex in the treatment of Dravet syndrome as well as orphan designations in both Dravet syndrome and Lennox-Gastaut syndrome, or LGS. GW is about to commence a full clinical development program for Epidiolex in the treatment of both Dravet syndrome and LGS, working with leading pediatric epilepsy specialists across the U.S. The first Phase 2/3 clinical trial is due to commence in the coming weeks.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use